GITNUXREPORT 2026

Colonoscopy Statistics

Colonoscopy is a highly effective but unevenly accessed cancer screening procedure globally.

Min-ji Park

Research Analyst focused on sustainability and consumer trends.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

Perforation risk is 0.05-0.1% in screening colonoscopies.

Statistic 2

Bleeding after polypectomy occurs in 0.3-1% of procedures.

Statistic 3

Sedation-related cardiopulmonary events happen in 0.2% of cases.

Statistic 4

Post-colonoscopy appendicitis is reported in 0.024% of procedures.

Statistic 5

Splenic injury post-colonoscopy occurs at 0.0003-0.017% rate.

Statistic 6

Mortality from colonoscopy is 0.007-0.03 per 1000 procedures.

Statistic 7

Unrecognized perforation leads to surgery in 50% of cases.

Statistic 8

Post-polypectomy syndrome (burn) affects 0.003-0.1%.

Statistic 9

Delayed bleeding peaks at 0-2% for large polyp resections (>20mm).

Statistic 10

Infection transmission risk is <1 in 1 million with proper reprocessing.

Statistic 11

Vasovagal reactions occur in 0.5-1% during procedures.

Statistic 12

Bowel prep-related dehydration hospitalized 0.4% of outpatients.

Statistic 13

Therapeutic colonoscopy perforation rate is 0.3-0.5% vs 0.05% diagnostic.

Statistic 14

Anticoagulation increases bleeding risk 2-5 fold post-polypectomy.

Statistic 15

Elderly (>80) have 3x higher perforation risk (0.2%).

Statistic 16

Female gender raises perforation odds by 2.5 times.

Statistic 17

Inpatient colonoscopy perforation is 0.16-0.2%.

Statistic 18

Propofol sedation reduces hypoxia to 0.1% vs midazolam.

Statistic 19

Diverticular bleeding post-procedure is 0.1-0.5%.

Statistic 20

U.S. annual colonoscopy cost averages $1,250-$3,000 per procedure.

Statistic 21

Medicare reimburses $200-$500 for screening colonoscopy.

Statistic 22

Lifetime cost savings from screening: $10,000-$20,000 per prevented CRC.

Statistic 23

U.S. total colorectal screening costs $10-15 billion yearly.

Statistic 24

FIT testing costs $20-50 vs $1,000+ colonoscopy, more cost-effective initially.

Statistic 25

Polypectomy during colonoscopy saves $2,500 per polyp removed vs surgery.

Statistic 26

Uninsured face $2,000 out-of-pocket, reducing uptake by 40%.

Statistic 27

EU countries: colonoscopy costs €300-800, subsidized 80-100%.

Statistic 28

ROI of screening programs: $3-7 saved per $1 spent.

Statistic 29

Hospital-based colonoscopy $1,800 vs ambulatory $900.

Statistic 30

Bowel prep costs $50-100, impacts 20% non-completion.

Statistic 31

Lost productivity from prep day: $250 average per patient.

Statistic 32

CRC treatment costs $80,000/year vs screening prevention $1,200.

Statistic 33

ACA expanded coverage, increasing screening by 5%, saving $1B.

Statistic 34

Global CRC screening investment gap: $50 billion needed by 2030.

Statistic 35

Anesthesia fees add $200-400 to procedure cost.

Statistic 36

Surveillance intervals reduce costs by 30% vs annual.

Statistic 37

Pathology costs post-polypectomy: $100-300 per specimen.

Statistic 38

Telehealth prep counseling cuts no-show rates 15%, saving $500k/year per center.

Statistic 39

U.S. adults 45-75: 67% screened, whites 70%, Blacks 64%, Hispanics 52%, Asians 52%.

Statistic 40

Men have 10-15% higher adenoma detection rates than women.

Statistic 41

African Americans recommended screening start at age 45, uptake 62%.

Statistic 42

Age 65-74 group has highest screening rate at 75%.

Statistic 43

Low-income (<$25k) screening rate 55% vs high-income 75%.

Statistic 44

Rural residents 58% screened vs 68% urban.

Statistic 45

Hispanics face language barriers, screening 45-50%.

Statistic 46

Smokers have 20% lower colonoscopy adherence.

Statistic 47

Diabetics undergo colonoscopy 10% more frequently due to surveillance.

Statistic 48

Obesity (BMI>30) correlates with 15% lower completion rates.

Statistic 49

Family history patients: 80% compliance with earlier screening.

Statistic 50

College-educated have 75% screening vs 50% no high school.

Statistic 51

Women aged 50-64: 65% screened, men 70%.

Statistic 52

Native Americans screening rate 48%, lowest among groups.

Statistic 53

Insured populations 75% screened vs uninsured 30%.

Statistic 54

Southern U.S. states average 60% screening, Northeast 72%.

Statistic 55

LGBTQ+ individuals have 5-10% lower screening rates.

Statistic 56

Immigrants (1st gen) screening 40% vs native-born 70%.

Statistic 57

Veterans: 85% screening rate, higher compliance.

Statistic 58

In 2019, average age for colonoscopy was 62 years, with 55% female patients.

Statistic 59

Blacks have 20% higher CRC incidence, yet 5% lower screening rates.

Statistic 60

In the United States, approximately 14 million colonoscopies are performed annually for screening, surveillance, and diagnostic purposes.

Statistic 61

Globally, colorectal cancer screening via colonoscopy reaches only about 40% of eligible adults in high-income countries.

Statistic 62

In 2020, the U.S. colonoscopy screening rate among adults aged 50-75 was 67.3%, up from 62.6% in 2016.

Statistic 63

European countries average 25-50% colonoscopy uptake for colorectal cancer screening programs.

Statistic 64

In Japan, over 50% of individuals aged 50 and older undergo colonoscopy within recommended intervals.

Statistic 65

U.S. Medicare beneficiaries had a colonoscopy screening rate of 75% in 2019 for ages 65-75.

Statistic 66

In Australia, 39.7% of adults aged 50-74 reported colonoscopy in the past 5 years as of 2020.

Statistic 67

Canada sees about 1.2 million colonoscopies yearly, with screening adherence at 60% for FIT-positive follow-ups.

Statistic 68

In the UK, colonoscopy utilization for symptomatic patients increased 20% from 2015-2020.

Statistic 69

Brazil reports low colonoscopy rates at 15% for screening in urban populations.

Statistic 70

South Korea's national screening program achieves 70% colonoscopy follow-up for positive FIT tests.

Statistic 71

In Germany, 30% of target population participated in colonoscopy-based screening by 2022.

Statistic 72

U.S. rural areas have 10% lower colonoscopy screening rates than urban (58% vs 68%).

Statistic 73

India has colonoscopy access limited to <5% of at-risk population annually.

Statistic 74

New Zealand Maori population colonoscopy screening rate is 45%, lower than non-Maori 55%.

Statistic 75

France mandates colonoscopy for 10% of FIT positives, with overall screening at 35%.

Statistic 76

In Sweden, 62% adherence to colonoscopy after positive fecal test.

Statistic 77

U.S. Asian Americans have the lowest colonoscopy rates at 52% vs 70% whites.

Statistic 78

Italy's organized screening programs reach 45% colonoscopy uptake.

Statistic 79

China urban colonoscopy screening is 20%, rural <10%.

Statistic 80

Netherlands achieves 80% colonoscopy compliance post-FIT positive.

Statistic 81

U.S. 2022 data shows 23 million screening colonoscopies performed yearly.

Statistic 82

Spain's screening colonoscopy rate is 38% for ages 50-69.

Statistic 83

Poland reports 25% population coverage for colonoscopy screening.

Statistic 84

U.S. veterans have 85% colonoscopy screening rates.

Statistic 85

Singapore's program sees 55% colonoscopy follow-up.

Statistic 86

40% of U.S. colonoscopies are for surveillance post-polyp.

Statistic 87

Colonoscopy detects 95% of large adenomas (>1cm) during screening.

Statistic 88

Polyp detection rate (PDR) in screening colonoscopy averages 25-30% in U.S. practices.

Statistic 89

Adenoma detection rate (ADR) benchmark is >25% for men and >15% for women aged 50+.

Statistic 90

Right-sided colon lesions are missed in 2-6% of colonoscopies without complete intubation.

Statistic 91

High-definition colonoscopy improves ADR by 8% over standard.

Statistic 92

Cecal intubation rate exceeds 95% in quality programs.

Statistic 93

Narrow-band imaging increases detection of flat lesions by 10-20%.

Statistic 94

Screening colonoscopy reduces colorectal cancer incidence by 68% in 10 years.

Statistic 95

Interval CRC rate post-colonoscopy is 0.5-1% due to missed lesions.

Statistic 96

Bowel preparation quality affects ADR; adequate prep yields 30% ADR.

Statistic 97

Tandem colonoscopy shows miss rate of 22% for polyps.

Statistic 98

AI-assisted colonoscopy boosts ADR by 14-50% in trials.

Statistic 99

Sessile serrated lesion detection rate averages 5-10% in screening.

Statistic 100

Colonoscopy prevents 80% of colorectal cancer deaths in screened cohorts.

Statistic 101

Withdrawal time >6 minutes correlates with 20% higher ADR.

Statistic 102

Chromoendoscopy detects 15% more adenomas in high-risk patients.

Statistic 103

Screening colonoscopy finds cancer in 0.5-1% of average-risk patients.

Statistic 104

Advanced neoplasia detection rate is 6-10% in first screening.

Statistic 105

Endocuff increases ADR by 11% in randomized trials.

Statistic 106

Full-spectrum colonoscopy reduces miss rate to 7% vs 25% standard.

Statistic 107

In surveillance, ADR >30% for high-risk prior adenoma patients.

Statistic 108

Colonoscopy sensitivity for CRC is 94.7% per patient basis.

Statistic 109

Withdrawal time metric: 90% of procedures >6 min in quality centers.

Statistic 110

Serrated polyposis syndrome detected in 1:3000 colonoscopies.

1/110

Sources

Trusted by 500+ publications

+497

While millions of Americans get colonoscopies each year, a surprisingly low global screening rate highlights a critical gap in colorectal cancer prevention that demands urgent attention.

Key Takeaways

In the United States, approximately 14 million colonoscopies are performed annually for screening, surveillance, and diagnostic purposes.
Globally, colorectal cancer screening via colonoscopy reaches only about 40% of eligible adults in high-income countries.
In 2020, the U.S. colonoscopy screening rate among adults aged 50-75 was 67.3%, up from 62.6% in 2016.
Colonoscopy detects 95% of large adenomas (>1cm) during screening.
Polyp detection rate (PDR) in screening colonoscopy averages 25-30% in U.S. practices.
Adenoma detection rate (ADR) benchmark is >25% for men and >15% for women aged 50+.
Perforation risk is 0.05-0.1% in screening colonoscopies.
Bleeding after polypectomy occurs in 0.3-1% of procedures.
Sedation-related cardiopulmonary events happen in 0.2% of cases.
U.S. adults 45-75: 67% screened, whites 70%, Blacks 64%, Hispanics 52%, Asians 52%.
Men have 10-15% higher adenoma detection rates than women.
African Americans recommended screening start at age 45, uptake 62%.
U.S. annual colonoscopy cost averages $1,250-$3,000 per procedure.
Medicare reimburses $200-$500 for screening colonoscopy.
Lifetime cost savings from screening: $10,000-$20,000 per prevented CRC.

Colonoscopy is a highly effective but unevenly accessed cancer screening procedure globally.

Complications and Risks

Perforation risk is 0.05-0.1% in screening colonoscopies.
Bleeding after polypectomy occurs in 0.3-1% of procedures.
Sedation-related cardiopulmonary events happen in 0.2% of cases.
Post-colonoscopy appendicitis is reported in 0.024% of procedures.
Splenic injury post-colonoscopy occurs at 0.0003-0.017% rate.
Mortality from colonoscopy is 0.007-0.03 per 1000 procedures.
Unrecognized perforation leads to surgery in 50% of cases.
Post-polypectomy syndrome (burn) affects 0.003-0.1%.
Delayed bleeding peaks at 0-2% for large polyp resections (>20mm).
Infection transmission risk is <1 in 1 million with proper reprocessing.
Vasovagal reactions occur in 0.5-1% during procedures.
Bowel prep-related dehydration hospitalized 0.4% of outpatients.
Therapeutic colonoscopy perforation rate is 0.3-0.5% vs 0.05% diagnostic.
Anticoagulation increases bleeding risk 2-5 fold post-polypectomy.
Elderly (>80) have 3x higher perforation risk (0.2%).
Female gender raises perforation odds by 2.5 times.
Inpatient colonoscopy perforation is 0.16-0.2%.
Propofol sedation reduces hypoxia to 0.1% vs midazolam.
Diverticular bleeding post-procedure is 0.1-0.5%.

Complications and Risks Interpretation

While the statistics confirm a colonoscopy is remarkably safe overall, they also serve as a sobering reminder that for the unlucky few who draw the short straw, the complications can range from inconveniently unpleasant to life-alteringly severe.

Costs and Economic Impact

U.S. annual colonoscopy cost averages $1,250-$3,000 per procedure.
Medicare reimburses $200-$500 for screening colonoscopy.
Lifetime cost savings from screening: $10,000-$20,000 per prevented CRC.
U.S. total colorectal screening costs $10-15 billion yearly.
FIT testing costs $20-50 vs $1,000+ colonoscopy, more cost-effective initially.
Polypectomy during colonoscopy saves $2,500 per polyp removed vs surgery.
Uninsured face $2,000 out-of-pocket, reducing uptake by 40%.
EU countries: colonoscopy costs €300-800, subsidized 80-100%.
ROI of screening programs: $3-7 saved per $1 spent.
Hospital-based colonoscopy $1,800 vs ambulatory $900.
Bowel prep costs $50-100, impacts 20% non-completion.
Lost productivity from prep day: $250 average per patient.
CRC treatment costs $80,000/year vs screening prevention $1,200.
ACA expanded coverage, increasing screening by 5%, saving $1B.
Global CRC screening investment gap: $50 billion needed by 2030.
Anesthesia fees add $200-400 to procedure cost.
Surveillance intervals reduce costs by 30% vs annual.
Pathology costs post-polypectomy: $100-300 per specimen.
Telehealth prep counseling cuts no-show rates 15%, saving $500k/year per center.

Costs and Economic Impact Interpretation

The American healthcare system spends billions on colonoscopies, a procedure that can cost patients thousands but saves society even more, yet we still make it so financially awkward that many avoid it altogether despite the clear economic and personal benefits.

Patient Demographics

U.S. adults 45-75: 67% screened, whites 70%, Blacks 64%, Hispanics 52%, Asians 52%.
Men have 10-15% higher adenoma detection rates than women.
African Americans recommended screening start at age 45, uptake 62%.
Age 65-74 group has highest screening rate at 75%.
Low-income (<$25k) screening rate 55% vs high-income 75%.
Rural residents 58% screened vs 68% urban.
Hispanics face language barriers, screening 45-50%.
Smokers have 20% lower colonoscopy adherence.
Diabetics undergo colonoscopy 10% more frequently due to surveillance.
Obesity (BMI>30) correlates with 15% lower completion rates.
Family history patients: 80% compliance with earlier screening.
College-educated have 75% screening vs 50% no high school.
Women aged 50-64: 65% screened, men 70%.
Native Americans screening rate 48%, lowest among groups.
Insured populations 75% screened vs uninsured 30%.
Southern U.S. states average 60% screening, Northeast 72%.
LGBTQ+ individuals have 5-10% lower screening rates.
Immigrants (1st gen) screening 40% vs native-born 70%.
Veterans: 85% screening rate, higher compliance.
In 2019, average age for colonoscopy was 62 years, with 55% female patients.
Blacks have 20% higher CRC incidence, yet 5% lower screening rates.

Patient Demographics Interpretation

The data paints a stark portrait of American healthcare: our collective gut check reveals that the path to a lifesaving colonoscopy is frustratingly uneven, mapped by disparities in wealth, race, geography, and education rather than by medical need alone.

Prevalence and Utilization

In the United States, approximately 14 million colonoscopies are performed annually for screening, surveillance, and diagnostic purposes.
Globally, colorectal cancer screening via colonoscopy reaches only about 40% of eligible adults in high-income countries.
In 2020, the U.S. colonoscopy screening rate among adults aged 50-75 was 67.3%, up from 62.6% in 2016.
European countries average 25-50% colonoscopy uptake for colorectal cancer screening programs.
In Japan, over 50% of individuals aged 50 and older undergo colonoscopy within recommended intervals.
U.S. Medicare beneficiaries had a colonoscopy screening rate of 75% in 2019 for ages 65-75.
In Australia, 39.7% of adults aged 50-74 reported colonoscopy in the past 5 years as of 2020.
Canada sees about 1.2 million colonoscopies yearly, with screening adherence at 60% for FIT-positive follow-ups.
In the UK, colonoscopy utilization for symptomatic patients increased 20% from 2015-2020.
Brazil reports low colonoscopy rates at 15% for screening in urban populations.
South Korea's national screening program achieves 70% colonoscopy follow-up for positive FIT tests.
In Germany, 30% of target population participated in colonoscopy-based screening by 2022.
U.S. rural areas have 10% lower colonoscopy screening rates than urban (58% vs 68%).
India has colonoscopy access limited to <5% of at-risk population annually.
New Zealand Maori population colonoscopy screening rate is 45%, lower than non-Maori 55%.
France mandates colonoscopy for 10% of FIT positives, with overall screening at 35%.
In Sweden, 62% adherence to colonoscopy after positive fecal test.
U.S. Asian Americans have the lowest colonoscopy rates at 52% vs 70% whites.
Italy's organized screening programs reach 45% colonoscopy uptake.
China urban colonoscopy screening is 20%, rural <10%.
Netherlands achieves 80% colonoscopy compliance post-FIT positive.
U.S. 2022 data shows 23 million screening colonoscopies performed yearly.
Spain's screening colonoscopy rate is 38% for ages 50-69.
Poland reports 25% population coverage for colonoscopy screening.
U.S. veterans have 85% colonoscopy screening rates.
Singapore's program sees 55% colonoscopy follow-up.
40% of U.S. colonoscopies are for surveillance post-polyp.

Prevalence and Utilization Interpretation

While the world offers a patchwork of diligence in colonoscopy screening, the persistent gaps reveal a universal irony: we’ve invented a brilliant defense against a preventable killer, yet convincing ourselves to use it remains the hardest part.

Procedure Efficacy

Colonoscopy detects 95% of large adenomas (>1cm) during screening.
Polyp detection rate (PDR) in screening colonoscopy averages 25-30% in U.S. practices.
Adenoma detection rate (ADR) benchmark is >25% for men and >15% for women aged 50+.
Right-sided colon lesions are missed in 2-6% of colonoscopies without complete intubation.
High-definition colonoscopy improves ADR by 8% over standard.
Cecal intubation rate exceeds 95% in quality programs.
Narrow-band imaging increases detection of flat lesions by 10-20%.
Screening colonoscopy reduces colorectal cancer incidence by 68% in 10 years.
Interval CRC rate post-colonoscopy is 0.5-1% due to missed lesions.
Bowel preparation quality affects ADR; adequate prep yields 30% ADR.
Tandem colonoscopy shows miss rate of 22% for polyps.
AI-assisted colonoscopy boosts ADR by 14-50% in trials.
Sessile serrated lesion detection rate averages 5-10% in screening.
Colonoscopy prevents 80% of colorectal cancer deaths in screened cohorts.
Withdrawal time >6 minutes correlates with 20% higher ADR.
Chromoendoscopy detects 15% more adenomas in high-risk patients.
Screening colonoscopy finds cancer in 0.5-1% of average-risk patients.
Advanced neoplasia detection rate is 6-10% in first screening.
Endocuff increases ADR by 11% in randomized trials.
Full-spectrum colonoscopy reduces miss rate to 7% vs 25% standard.
In surveillance, ADR >30% for high-risk prior adenoma patients.
Colonoscopy sensitivity for CRC is 94.7% per patient basis.
Withdrawal time metric: 90% of procedures >6 min in quality centers.
Serrated polyposis syndrome detected in 1:3000 colonoscopies.

Procedure Efficacy Interpretation

While the colonoscopy's 95% success rate at spotting large growths is reassuring, the sobering 22% polyp miss rate reminds us this is a high-stakes game of hide-and-seek where the quality of the hunt, from preparation to withdrawal time, directly dictates whether we achieve that celebrated 80% reduction in cancer deaths.

Sources & References

Logos provided by Logo.dev